Infliximab (Remicade®, Inflectra®, Renflexis®, Avsola™)

Infliximab is covered for FDA‑approved indications (e.g., Crohn’s disease, ulcerative colitis, RA, PsA, plaque psoriasis, ankylosing spondylitis) and specified compendial/off‑label uses (e.g., Behçet’s disease, GVHD, hidradenitis suppurativa, uveitis, immunotherapy‑related toxicities); use outside these listed indications is not covered. Coverage requires indication‑specific prior therapy trials or contraindications, prescription/consultation by the specified specialist, age limits where noted, objective findings for some diagnoses, adherence to dosing/frequency and infusion documentation, and documented response for reauthorization.

"Crohn's disease"

Sign up to see full coverage criteria, indications, and limitations.